Idiopathic pulmonary fibrosis: treatment update
Oisin J O'Connell, Marcus P Kennedy, Michael T Henry
Advances in Therapy 2011, 28 (11): 986-99
21975927
Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. Despite multiple recent clinical trials, there is no strong evidence supporting a survival advantage for any agent in the management of patients with IPF. The limited effectiveness of current treatment regimes has led to a search for novel therapies including antifibrotic strategies. This article reviews the evidence supporting the treatments currently used in the management of IPF.
Full Text Links
Find Full Text Links for this Article
You are not logged in. Sign Up or Log In to join the discussion.